Check your eligibility
Question 1 of 3
Have you received a formal diagnosis for a health condition?
Latest from our blog
26. 05. 2026
Decoding Cannabis: what the first placebo-controlled cannabis migraine trial means for patients in 2026
The first randomised, placebo-controlled trial of vaporised cannabis for migraine attacks has finally been published. Researchers at UC San Diego compared THC, CBD, a balanced combination, and placebo across 247 treated migraines. The balanced ratio came out clearly ahead, with sustained benefit at 24 and 48 hours and no serious adverse events. We unpack what the trial proves, where it falls short, and how the results sit alongside Releaf's UK patient survey data on medical cannabis for migraine.
26. 05. 2026
19. 05. 2026
What the UK’s largest active medical cannabis patient survey revealed about gastroenterological conditions
96.1% of UK gastroenterological patients surveyed in Releaf’s 2025 medical cannabis survey said their prescribed medical cannabis treatment was effective at managing their symptoms, 97.4% reported improvements in their overall quality of life, and 98.7% said they would recommend medical cannabis treatment to someone with a similar qualifying condition.
19. 05. 2026
12. 05. 2026
International Nurses Day 2026: What role do medical cannabis nurses play in patient care?
International Nurses Day 2026 allows us to celebrate the incredible efforts nurses make to ensure patients feel supported throughout their treatment journey. In this article, we explore how Releaf’s medical cannabis nurses offer personalised follow-up care and practical guidance to help patients feel more confident after receiving their prescription.
12. 05. 2026